All In MedTech

FDA Clearance Tracker · P030040-S004

ADVIA CENTAUR HBC IGM READYPACK REAGENTS/QUALITY CONTROL MATERIALS

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Apr 9, 2009 (this decision)Source: openFDAMethods & limitations

PMA supplement

The decision

FDA number
P030040-S004
Device name
ADVIA CENTAUR HBC IGM READYPACK REAGENTS/QUALITY CONTROL MATERIALS
Applicant location
East Walpole, MA
Received
Mar 9, 2009
Decided
Apr 9, 2009
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P030040

Device type

Device class
Class II
Regulation
21 CFR 866.3172

Every decision under product code LOM

FDA's approval statement

As written in FDA's record.

APPROVAL FOR ADDING ADVIA CENTAUR XP INSTRUMENT TO THE INTENDED USE OF THE APPROVED DEVICE ADVIA CENTAUR HBC IGM ASSAY. THE DEVICE, AS MODIFIED, WILL BE MARKETEDUNDER THE TRADE NAME ADVIA CENTAUR HBC IGM ASSAY AND IS INDICATED FOR:THE ADVIA CENTAUR HBC IGM ASSAY IS AN IN VITRO DIAGNOSTIC TEST FOR THE QUALITATIVEDETERMINATION OF IGM RESPONSE TO HEPATITIS B VIRUS CORE ANTIGEN IN HUMAN SERUM ANDPLASMA (EDTA OR LITHIUM OR SODIUM HEPARINIZED) USING THE ADVIA CENTAUR AND ADVIACENTAUR XP SYSTEMS. THE ASSAY USES RECOMBINANT HBC ANTIGEN. THIS ASSAY MAY BE USED IN COMBINATION WITH OTHER HEPATITIS B VIRUS (HBV) MARKER ASSAYS TO DEFINE THE CLINICAL STATUS OF KNOWN HBV INFECTED PATIENTS OR CAN BE COMBINED WITH OTHER HBV. HAV (HEPATITIS AVIRUS), AND HCV (HEPATITIS C VIRUS) ASSAYS FOR THE DIAGNOSIS OF PATIENTS PRESENTING SYMPTOMS OF ACUTE VIRAL HEPATITIS.ASSAY PERFORMANCE CHARACTERISTICS HAVE NOT BEEN ESTABLISHED FOR IMMUNOCOMPRO-MISED ORIMMUNOSUPPRESSED PATIENTS, CORD BLOOD, NEONATAL SPECIMENS, INFANTS, OR CHILDREN.ASSAY PERFORMANCE CHARACTERISTICS HAVE NOT BEEN ESTABLISHED WHEN THE ADVIA CENTAUR HBC IGM ASSAY IS USED IN CONJUNCTION WITH OTHER MANUFACTURERS' ASSAYS FOR SPECIFIC HBV SEROLOGICAL MARKERS.

Source documents

Other decisions for Siemens Healthcare Diagnostics

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.